Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14773312 | 0.91 | CACNA1C (0.56) | CACNA1C | |
| SCHEMBL17522884 | 0.86 | CYP3A4 (0.54) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL4094662 | 0.86 | CACNA1C (0.52) | CACNA1C | |
| SCHEMBL19797951 | 0.84 | CYP3A4 (0.52) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL16502228 | 0.84 | CYP3A4 (0.52) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL10280763 | 0.84 | CYP2C9 (0.49) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL3398742 | 0.83 | CYP3A4 (0.51) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL12318620 | 0.82 | CACNA1C (0.62) | CACNA1C | |
| SCHEMBL2840208 | 0.82 | CACNA1C (0.56) | CACNA1C | |
| SCHEMBL6120166 | 0.82 | CYP3A4 (0.46) | CYP2C9CYP3A4CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-13 | — | — | US | disclosed |
| US-8309558-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| US-8148382-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110256099-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP2C9 383/4885CYP3A4 299/4885CYP2C19 490/4885 |
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP2C9 383/4885CYP3A4 299/4885CYP2C19 490/4885 |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, SLC10A1 | CYP2C9 383/4885CYP3A4 299/4885CYP2C19 490/4885 |
| US-20110256099-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP2C9 383/4885CYP3A4 299/4885CYP2C19 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.